Prescient Therapeutics Limited (ASX:PTX)

Accolade Balance Sheet

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	6.39	10.49	5.9	12.26	16.1	7.36
Short-Term Investments	2.02	4.02	16.02	0.02	0.02	0.02
Cash & Short-Term Investments	8.41	14.51	21.92	12.28	16.12	7.38
Cash Growth	-54.41%	-33.78%	78.41%	-23.79%	118.48%	-23.63%
Accounts Receivable	5.19	3.92	2.58	1.72	1.24	1.06
Receivables	5.19	3.92	2.58	1.72	1.24	1.06
Prepaid Expenses	1.34	0.31	0.25	0.24	0.24	0.27
Total Current Assets	14.93	18.74	24.74	14.25	17.6	8.71
Property, Plant & Equipment	0	0	0	0	0	0
Other Intangible Assets	1.65	1.65	3.37	3.37	3.37	3.37
Total Assets	16.58	20.39	28.11	17.62	20.97	12.07
Accounts Payable	0.66	1.72	1.78	0.51	0.23	0.48
Accrued Expenses	0.24	0.22	0.2	0.12	0.07	0.05
Short-Term Debt	0.03	0.33	-	-	0.17	0.16
Other Current Liabilities	-	0.05	0.05	0.18	0.04	0.18
Total Current Liabilities	0.93	2.32	2.03	0.81	0.51	0.86
Total Liabilities	0.93	2.33	2.03	0.86	0.54	0.88
Common Stock	93.27	93.27	93.25	77.26	76.67	63.93
Retained Earnings	-79.31	-77.4	-69.31	-62.45	-57.51	-53.46
Comprehensive Income & Other	1.68	2.19	2.14	1.95	1.26	0.72
Shareholders' Equity	15.65	18.07	26.08	16.76	20.43	11.19
Total Liabilities & Equity	16.58	20.39	28.11	17.62	20.97	12.07
Total Debt	0.03	0.33	-	-	0.17	0.16
Net Cash (Debt)	8.37	14.18	21.92	12.28	15.95	7.22
Net Cash Growth	-54.59%	-35.28%	78.41%	-22.99%	120.93%	-25.25%
Net Cash Per Share	0.01	0.02	0.03	0.02	0.03	0.02
Filing Date Shares Outstanding	805.32	805.32	805.27	654.32	641.05	394.26
Total Common Shares Outstanding	805.32	805.32	805.27	654.32	641.05	394.26
Working Capital	13.99	16.42	22.71	13.44	17.08	7.84
Book Value Per Share	0.02	0.02	0.03	0.03	0.03	0.03
Tangible Book Value	14	16.42	22.71	13.4	17.06	7.82
Tangible Book Value Per Share	0.02	0.02	0.03	0.02	0.03	0.02

Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.